Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

GeoVax Labs, Inc. - Common Stock (NQ:GOVX)

0.7588 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,035
Open 0.7588
Bid (Size) 0.7734 (4)
Ask (Size) 0.7750 (4)
Prev. Close 0.7588
Today's Range 0.7588 - 0.7588
52wk Range 0.4300 - 9.560
Shares Outstanding 2,172,309
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
GeoVax Announces Allowance of Patent Protecting Multi-Antigen COVID-19 Vaccine Constructs
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Intellectual Property
GeoVax Announces Allowance of Patent Protecting Multi-Antigen COVID-19 Vaccine Constructs
Via TheNewswire.com
Topics Intellectual Property

Performance

YTD
-69.4%
-69.4%
1 Month
-7.5%
-7.5%
3 Month
-22.6%
-22.6%
6 Month
-55.6%
-55.6%
1 Year
-86.6%
-86.6%

More News

Read More
GeoVax to Present at the Emerging Growth Conference on August 20, 2025
Via NewMediaWire
GeoVax to Present at the Emerging Growth Conference on August 20, 2025
Via TheNewswire.com
GeoVax Comments on HHS mRNA Vaccine Rollback: Urges Full Embrace of MVA-Based Multi-Antigen Vaccine
Via NewMediaWire
GeoVax Comments on HHS mRNA Vaccine Rollback: Urges Full Embrace of MVA-Based Multi-Antigen Vaccine
Via TheNewswire.com
GeoVax Reports Second Quarter 2025 Financial Results and Provides Business Update
Via TheNewswire.com
GeoVax Announces Research Program to Evaluate Needle-Free, Self-Administered GEO-MVA Vaccine Using Vaxxas Microarray Patch Technology
Via TheNewswire.com
Earnings Preview For Geovax Labs
Via Benzinga
GeoVax Urges Immediate Action on Pandemic Preparedness as Biodefense Gaps Expose Fragile Supply Chains
Via NewMediaWire
GeoVax Urges Immediate Action on Pandemic Preparedness as Biodefense Gaps Expose Fragile Supply Chains
Via TheNewswire.com
GeoVax Accelerates Development of GEO-MVA Vaccine Amid Expanding Global Mpox Crisis and Reaffirmed WHO Emergency Designation
Via NewMediaWire
Topics Death
GeoVax Accelerates Development of GEO-MVA Vaccine Amid Expanding Global Mpox Crisis and Reaffirmed WHO Emergency Designation
Via TheNewswire.com
Topics Death
GeoVax Labs Revenue Doubles in Q2
Via The Motley Fool
Topics Intellectual Property
GeoVax to Advance Gedeptin(R) Into First-Line Therapy Neoadjuvant Combination Trial Following Landmark KEYNOTE-689 Results
Via TheNewswire.com
GeoVax Highlights EMA Regulatory Milestone as Catalyst for Near-Term Revenue from GEO-MVA Mpox Vaccine
Via TheNewswire.com
GeoVax Highlights Growing Urgency for Diversified Mpox Vaccine Supply as Global Outbreaks Expand
Via TheNewswire.com
GeoVax Reports Second Quarter 2025 Financial Results and Provides Business Update
Via NewMediaWire
GeoVax Announces Research Program to Evaluate Needle-Free, Self-Administered GEO-MVA Vaccine Using Vaxxas Microarray Patch Technology
Via NewMediaWire
Earnings Scheduled For July 28, 2025
Via Benzinga
GeoVax to Advance Gedeptin(R) Into First-Line Therapy Neoadjuvant Combination Trial Following Landmark KEYNOTE-689 Results
Via NewMediaWire
GeoVax to Report Second Quarter 2025 Financial Results and Provide Corporate Update on July 28, 2025
Via NewMediaWire
GeoVax to Report Second Quarter 2025 Financial Results and Provide Corporate Update on July 28, 2025
Via TheNewswire.com
GeoVax Highlights EMA Regulatory Milestone as Catalyst for Near-Term Revenue from GEO-MVA Mpox Vaccine
Via NewMediaWire
GeoVax Highlights Growing Urgency for Diversified Mpox Vaccine Supply as Global Outbreaks Expand
Via NewMediaWire

Frequently Asked Questions

Is GeoVax Labs, Inc. - Common Stock publicly traded?
Yes, GeoVax Labs, Inc. - Common Stock is publicly traded.
What exchange does GeoVax Labs, Inc. - Common Stock trade on?
GeoVax Labs, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for GeoVax Labs, Inc. - Common Stock?
The ticker symbol for GeoVax Labs, Inc. - Common Stock is GOVX on the Nasdaq Stock Market
What is the current price of GeoVax Labs, Inc. - Common Stock?
The current price of GeoVax Labs, Inc. - Common Stock is 0.7588
When was GeoVax Labs, Inc. - Common Stock last traded?
The last trade of GeoVax Labs, Inc. - Common Stock was at 08/20/25 04:00 PM ET
What is the market capitalization of GeoVax Labs, Inc. - Common Stock?
The market capitalization of GeoVax Labs, Inc. - Common Stock is 1.65M
How many shares of GeoVax Labs, Inc. - Common Stock are outstanding?
GeoVax Labs, Inc. - Common Stock has 2M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.